Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 735-739

  Bedikian, Agop Y ^a   Legha, Sewa S ^a   Eton, Omar ^a   Buzaid, Antonio C ^a   Papadopoulos, Nicholas ^a   Plager, Carl ^a   McIntyre, Susan ^a   Viallet, Jean ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Sanofi Synthelabo Research   (United States)

Author keywords

Chemotherapy; Cisplatin; Melanoma; Tirapazamine

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; MALE; MELANOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0033377322     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00007     Document Type: Article

References (11)

1. 1. Baker MA, Zeman EM, Hirst VK, et al. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 1988; 48: 5947-52.
2. 2. Cahill A, White INH. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1, 4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines. Carcinogenesis 1990; 11: 1407-11.
3. 3. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993; 53: 4633-6.
4. 4. Bedikian AY, Legha SS, Eton O, et al. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 1997; 8: 1-5.
5. (™) (tirapazamine)+cisplatin: safety and efficacy in advanced non-small cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol 1998; 17: 472 (abstr 1815).
6. (™) (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: final results from the international phase III CATAPULT I trial. Proc Am Soc Clin Oncol 1998; 17: 454a (abstr 1749).
7. 7. Prager TC, Kellaway J, Zou Y, Urso RG, McIntyre S, Bedikian AY. Evaluation of ocular safety: tirapazamine plus cisplatin in patients with metastatic melanoma. Anti-Cancer Drugs 1998; 9: 515-24.
8. 8. Elsaid AA, Menke D, Corie MJ, Brown JM. Anti-melanoma activity of tirapazamine in combination with dacarbazine (DTIC). Proc Am Soc Clin Oncol 1997; 16: 505a (abstr 1814).
9. 9. Dorie MJ, Brown JM. Modification of the anti-tumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 1997; 39: 361-6.
10. 10. Ng K, Treat J, O'Dwyer P, Friedland D, Miller VA. A phase I trial of the addition of paclitaxel to tirapazamine (TPZ) and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 496a (abstr 1910).
11. 11. Kim C, Pinto HA, Tate D, et al. Tirapazamine, cisplatin and fluorouracil as induction chemotherapy and simultaneous chemoradiotherapy for organ preservation in advanced head and neck cancer. Proc Am Soc Clin Oncol 1998; 17: 395a (abstr 1523).